PMID- 27526299
OWN - NLM
STAT- MEDLINE
DCOM- 20170314
LR  - 20170314
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Linking)
VI  - 29
DP  - 2016 Oct
TI  - Current and emerging therapies of HER2-positive metastatic breast cancer.
PG  - 170-7
LID - S0960-9776(16)30136-9 [pii]
LID - 10.1016/j.breast.2016.07.026 [doi]
AB  - The HER2 receptor as measured by immunohistochemistry (IHC) and fluorescence in 
      situ hybridization (FISH) is overexpressed in 15-20% of all breast cancers and 
      traditionally represents adverse biology and a guarded prognosis, particularly in 
      HER2 positive metastatic breast cancer (MBC). Trastuzumab and newer anti-HER2 
      targeting agents have significantly improved the clinical outcomes of patients 
      with HER2 positive MBC. The development of new techniques has led to discovery of 
      promising biomarkers that can lead to more precise selection of patients for 
      anti-HER2 therapies. This paper summarizes these new biomarkers, useful in 
      selecting patients for treatment with new and emerging therapies for HER2 
      positive MBC. Emerging next generation sequencing techniques have truly changed 
      the landscape of HER2 positive MBC. Deployment of multiple anti-HER2 therapies in 
      combination is a strategy which has yielded additive or even synergistic effects 
      and has led to markedly improved patient outcomes in HER2+ MBC. In the future, in 
      order to further improve the treatment of these patients and to reduce 
      toxicities, we need to improve our understanding of HER2-dependent pathways and 
      their function, and to develop further treatment combinations while optimizing 
      selection of patients by identifying new biomarkers. The results of prospective 
      studies using CTCs, cDNA and other promising new biomarkers are awaited with 
      great interest.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Hernandez-Blanquisett, Abraham
AU  - Hernandez-Blanquisett A
AD  - Cancer Center, Massachusetts General Hospital, Harvard University, USA.
FAU - Touya, Diego
AU  - Touya D
AD  - Department of Oncology, Hospital de Clinicas, Universidad de la Republica, 
      Uruguay.
FAU - Strasser-Weippl, Kathrin
AU  - Strasser-Weippl K
AD  - Center for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, 
      Austria.
FAU - Ruiz, Rossana
AU  - Ruiz R
AD  - Cancer Center, Massachusetts General Hospital, Harvard University, USA.
FAU - St Louis, Jessica
AU  - St Louis J
AD  - Cancer Center, Massachusetts General Hospital, Harvard University, USA.
FAU - Goss, Paul
AU  - Goss P
AD  - Cancer Center, Massachusetts General Hospital, Harvard University, USA. 
      Electronic address: pgoss@partners.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160813
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Biomarkers, Tumor/analysis
MH  - Breast Neoplasms/chemistry/*drug therapy/pathology
MH  - Female
MH  - High-Throughput Nucleotide Sequencing/trends
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Receptor, ErbB-2/*antagonists & inhibitors/metabolism
OTO - NOTNLM
OT  - Biomarkers
OT  - Breast cancer
OT  - Endocrine therapy
OT  - HER2
OT  - Metastatic
OT  - Targeted therapy
EDAT- 2016/08/16 06:00
MHDA- 2017/03/16 06:00
CRDT- 2016/08/16 06:00
PHST- 2016/03/23 00:00 [received]
PHST- 2016/07/18 00:00 [revised]
PHST- 2016/07/27 00:00 [accepted]
PHST- 2016/08/16 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
AID - S0960-9776(16)30136-9 [pii]
AID - 10.1016/j.breast.2016.07.026 [doi]
PST - ppublish
SO  - Breast. 2016 Oct;29:170-7. doi: 10.1016/j.breast.2016.07.026. Epub 2016 Aug 13.